Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Single-action versus dual-action antidepressants.

Rakesh Jain1

  • 1Department of Psychiatry, University of Texas Medical School, Houston, USA.

Primary Care Companion to the Journal of Clinical Psychiatry
|July 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A European perspective on tardive dyskinesia.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2025
Same author

Health-related behavioral changes following the use of psychedelics in naturalistic settings.

Preventive medicine reports·2025
Same author

Healthcare Resource Utilization 6 Months Before and After Olanzapine/Samidorphan Initiation: Real-World Assessment of Patients with Schizophrenia or Bipolar I Disorder.

Advances in therapy·2025
Same author

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.

Psychedelic medicine (New Rochelle, N.Y.)·2025
Same author

Dysregulation of Noradrenergic Activity: Its Role in Conceptualizing and Treating Major Depressive Disorder, Schizophrenia, Agitation in Alzheimer's Disease, and Posttraumatic Stress Disorder.

The Journal of clinical psychiatry·2024
Same author

Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial.

Journal of psychopharmacology (Oxford, England)·2024

Selective serotonin reuptake inhibitors (SSRIs) offer better side effects than older antidepressants but may be less effective. Newer serotonin-norepinephrine reuptake inhibitors (SNRIs) may provide a balance of efficacy and safety for depression treatment.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are widely used antidepressants due to favorable side effect profiles compared to tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).
  • SSRIs primarily act by inhibiting serotonin reuptake, offering a simpler mechanism than TCAs and MAOIs which affect multiple neurotransmitters.
  • The selectivity of SSRIs, while improving tolerability, may compromise their antidepressant efficacy, leading to slower onset, lower remission rates, and reduced effectiveness for physical depression symptoms.

Purpose of the Study:

  • To compare the efficacy and side effect profiles of different classes of antidepressants.
  • To evaluate the potential benefits of newer dual-action antidepressants over traditional single-action SSRIs.
  • To inform clinical practice regarding optimal antidepressant selection based on patient needs and symptom presentation.

Related Experiment Videos

Main Methods:

  • Comparative analysis of antidepressant mechanisms of action (SSRIs, TCAs, MAOIs).
  • Review of clinical data on antidepressant onset of action, remission rates, and symptom management.
  • Examination of the pharmacological properties of novel serotonin-norepinephrine reuptake inhibitors (SNRIs).

Main Results:

  • SSRIs demonstrate improved side effect profiles but may exhibit reduced antidepressant efficacy compared to TCAs and MAOIs.
  • TCAs and MAOIs, despite more side effects, may be more effective for certain depressive symptoms.
  • Emerging SNRIs present a dual-action mechanism with potentially fewer side effects than older dual-action drugs and greater efficacy than SSRIs.

Conclusions:

  • The choice of antidepressant involves balancing efficacy and side effect profiles.
  • SSRIs may not be optimal for all patients, particularly those with severe physical depressive symptoms.
  • SNRIs represent a promising therapeutic option, potentially offering enhanced antidepressant effects with improved tolerability.